CDK Global, Inc. Announces Early Results of Its Tender Offer and Consent Solicitation for Its 2024 Notes
CDK Global announced early results of its tender offer for 4.500% Senior Notes due 2024, with a current interest rate of 5.000%. As of May 6, 2022, holders of 82.5% of the $500 million principal amount validly tendered their notes. The company has received consents for proposed amendments to the indenture, eliminating certain restrictive covenants. The tender offer is set to expire on May 20, 2022. This process aligns with an acquisition plan by Central Parent LLC, which is expected to be finalized in Q3 2022, contingent upon financing and other conditions.
- Received consents from holders of over 50% of the 2024 Notes, allowing proposed amendments to take effect.
- 82.5% of the outstanding principal amount of 2024 Notes was tendered by the deadline.
- The completion of the tender offer and proposed amendments is contingent upon receiving financing and other customary conditions.
HOFFMAN ESTATES, Ill., May 09, 2022 (GLOBE NEWSWIRE) -- CDK Global, Inc. (Nasdaq: CDK) (“CDK” or the “Company”), a leading automotive retail technology company, today announced the early results of its previously announced tender offer (the “Tender Offer”) relating to any and all of its issued and outstanding
The following table sets forth certain information regarding the 2024 Notes and the Tender Offer, including the percentage of the outstanding aggregate principal amount of 2024 Notes that was validly tendered and not validly withdrawn on or prior to 5:00 P.M., New York City time, on May 6, 2022 (such time and date, as the same may be extended with respect to a Tender Offer, the “Consent Time”):
| CUSIP Nos. | ISIN Nos. | Outstanding Principal Amount | Title of Security | Purchase Price(1)(2) | Consent Payment (1)(2) | Total Consideration(1) | Percentage of Principal Amount Tendered | |||||
| 12508EAD3 | US12508EAD31 | 82.5 | % | |||||||||
_________________________
(1) Per
(2) Included in Total Consideration.
(3) Original interest rate. Pursuant to the terms of the 2024 Notes, the interest rate adjusts from time to time and is currently
As previously announced, CDK has received the consents to the Proposed Amendments from holders of greater than a majority of the outstanding aggregate principal amount of the 2024 Notes. Accordingly, the withdrawal deadline (the “Withdrawal Deadline”) for the 2024 Notes has occurred and previously tendered 2024 Notes may no longer be withdrawn and consents may no longer be revoked, and holders who tender 2024 Notes after the Withdrawal Deadline will not have the right to withdraw such tendered 2024 Notes or to revoke consents to the adoption of the Proposed Amendments. The supplemental indenture to the Indenture was executed on May 3, 2022 (the “Supplemental Indenture”) and, as a result, the Proposed Amendments became effective; however, the Proposed Amendments will not become operative unless the tendered 2024 Notes have been accepted for purchase by CDK on the acceptance date (the “Acceptance Date”) and the Acquisition (as defined below) has been consummated.
The Tender Offer is currently scheduled to expire at 12:00 midnight, New York City time, at the end of the day on May 20, 2022, unless extended (such time and date, as the same may be extended, the “Expiration Date”). Holders of 2024 Notes who validly tendered (and did not validly withdraw) their 2024 Notes and validly delivered (and did not validly revoke) their corresponding consents at or prior to the Consent Time, and whose 2024 Notes are accepted for purchase, will receive the Total Consideration per
CDK undertook the Tender Offer and the Solicitation in connection with the Agreement and Plan of Merger, dated as of April 7, 2022, by and among Central Parent LLC, a Delaware limited liability company (the “Acquiror”), Central Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of the Acquiror (“Merger Sub”), and CDK, as amended from time to time, pursuant to which Merger Sub will be merged with and into CDK, with CDK surviving such merger as a wholly-owned subsidiary of the Acquiror (such transaction, the “Acquisition”). The Acquiror is an affiliate of Brookfield Asset Management Inc. and Brookfield Capital Partners VI L.P. CDK anticipates that the Acquisition will be completed in the third quarter of 2022 and intends to extend the Expiration Date for the Tender Offer, without extending the Withdrawal Deadline (unless required by law) to have the Acceptance Date and Settlement Date coincide with the closing of the Acquisition.
If the Tender Offer is consummated and the Proposed Amendments become operative, the 2024 Notes that remain outstanding will not benefit from any of the restrictive covenants that are eliminated by the adoption of the Proposed Amendments and the Acquisition will not trigger the requirement that the Company make a Change of Control Offer under the Indenture.
The consummation of the Tender Offer (including to pay the Consent Payment) remains conditioned upon (1) the receipt by CDK of net proceeds from a financing on terms and conditions satisfactory to CDK, which will be sufficient to fund the Total Consideration in respect of all 2024 Notes (regardless of the actual amount of any 2024 Notes tendered) and estimated fees and expenses relating to the Tender Offer and Solicitation, (2) the consummation of the Acquisition and (3) satisfaction of certain other customary conditions. Holders who validly tender and do not validly withdraw their 2024 Notes prior to the Withdrawal Deadline and who validly deliver and do not validly revoke the corresponding consent at or prior to the Consent Time and whose 2024 Notes are accepted for purchase will not be paid the Total Consideration (including the Consent Payment) or the Purchase Price, as applicable, until the Settlement Date, and CDK's obligation to accept 2024 Notes for purchase and pay such amounts remain subject to the conditions described above.
This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders or consents with respect to, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful. The Tender Offer will only be made pursuant to the terms of the Offer to Purchase and Consent Solicitation Statement.
Holders may obtain copies of the Offer to Purchase and Consent Solicitation Statement from the Information Agent and Tender Agent for the Tender Offer, D.F. King & Co., Inc., at (212) 269-5550 (collect, for banks and brokers only) and (888) 540-8736 (toll free).
Credit Suisse Securities (USA) LLC is the Dealer Manager for the Tender Offer and Solicitation Agent for the Solicitation. Questions regarding the Tender Offer and Solicitation may be directed to Credit Suisse Securities (USA) LLC at (800) 820-1653 (toll free) and (212) 325-2476 (collect).
None of CDK, the Dealer Manager and Solicitation Agent, the Information Agent and Tender Agent or any other person makes any recommendation as to whether holders of 2024 Notes should tender their 2024 Notes or provide the related consents, and no one has been authorized to make such a recommendation.
About CDK Global, Inc.
With approximately
Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. By their nature, forward-looking statements involve risks and uncertainty because they relate to events and depend on circumstances that will occur in the future, and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements include, among other things, statements about the ability of the parties to complete the proposed transaction and the expected timing of completion of the proposed transaction; as well as any assumptions underlying any of the foregoing.
The following are some of the factors that could cause actual future results to differ materially from those expressed in any forward-looking statements: (i) uncertainties as to the timing of, and the Company’s ability to complete, the debt tender offers and solicitations, (ii) uncertainties as to the timing of the equity tender offer and the merger; (iii) the risk that the proposed transaction may not be completed in a timely manner or at all; (iv) uncertainties as to the percentage of the Company’s stockholders tendering their shares of common stock in the equity tender offer; (v) the possibility that competing offers or acquisition proposals for the Company will be made; (vi) the possibility that any or all of the various conditions to the consummation of the tender offer or the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (vii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, including in circumstances that would require the Company to pay a termination fee or other expenses; (viii) the effect of this announcement or pendency of the proposed transaction on the Company’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; (ix) risks related to diverting management’s attention from the Company’s ongoing business operations; (x) the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; and (xi) other factors as set forth from time to time in the Company’s filings with the SEC, including its annual report on Form 10-K for the fiscal year ended June 30, 2021 and any subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are based on information currently available to the Company, and the Company expressly disclaims any intent or obligation to update, supplement or revise publicly these forward-looking statements except as required by law.
Media Contacts:
Tony Macrito
630.805.0782
Tony.Macrito@cdk.com
Investor Relations Contact:
Reuben Gallegos
847.542.3254
Reuben.Gallegos@cdk.com
FAQ
What is the current status of CDK's tender offer for 2024 Notes?
What amendments are being made to the 4.500% Senior Notes due 2024?
What is the significance of the tender offer for CDK Global's future?
What conditions must be met for the tender offer to close?
